These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21083258)

  • 21. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease.
    Bauer M; Langer O; Dal-Bianco P; Karch R; Brunner M; Abrahim A; Lanzenberger R; Hofmann A; Joukhadar C; Carminati P; Ghirardi O; Piovesan P; Forloni G; Corrado ME; Lods N; Dudczak R; Auff E; Kletter K; Müller M
    Clin Pharmacol Ther; 2006 Sep; 80(3):216-27. PubMed ID: 16952488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacokinetic and metabolic studies in the development of drugs].
    Vereczkey L
    Acta Pharm Hung; 1995 Jul; 65(4):105-11. PubMed ID: 7572191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expanding utility of microdosing.
    Lappin G
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):401-6. PubMed ID: 27137711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early prediction of drug metabolism and toxicity: systems biology approach and modeling.
    Bugrim A; Nikolskaya T; Nikolsky Y
    Drug Discov Today; 2004 Feb; 9(3):127-35. PubMed ID: 14960390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.
    Bosgra S; Vlaming ML; Vaes WH
    Clin Pharmacokinet; 2016 Jan; 55(1):1-15. PubMed ID: 26242381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Approaches using molecular imaging technology -- use of PET in clinical microdose studies.
    Wagner CC; Langer O
    Adv Drug Deliv Rev; 2011 Jun; 63(7):539-46. PubMed ID: 20887762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals.
    Salehpour M; Ekblom J; Sabetsky V; Håkansson K; Possnert G
    Rapid Commun Mass Spectrom; 2010 May; 24(10):1481-9. PubMed ID: 20411588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of PBPK modelling in drug discovery and development at Pfizer.
    Jones HM; Dickins M; Youdim K; Gosset JR; Attkins NJ; Hay TL; Gurrell IK; Logan YR; Bungay PJ; Jones BC; Gardner IB
    Xenobiotica; 2012 Jan; 42(1):94-106. PubMed ID: 22035569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact?
    Boyd RA; Lalonde RL
    Clin Pharmacol Ther; 2007 Jan; 81(1):24-6. PubMed ID: 17185993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microdosing as a Potential Tool to Enhance Clinical Development of Novel Antibiotics: A Tissue and Plasma PK Feasibility Study with Ciprofloxacin.
    Oesterreicher Z; Eberl S; Wulkersdorfer B; Matzneller P; Eder C; van Duijn E; Vaes WHJ; Reiter B; Stimpfl T; Jäger W; Nussbaumer-Proell A; Marhofer D; Marhofer P; Langer O; Zeitlinger M
    Clin Pharmacokinet; 2022 May; 61(5):697-707. PubMed ID: 34997559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Utility of a microdose study for drug discovery and development].
    Yamaura Y
    Nihon Yakurigaku Zasshi; 2013 Mar; 141(3):126-30. PubMed ID: 23470476
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.
    Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Houston B; Oosterhuis B; Bjerrum OJ; Rowland M; Garner C
    Eur J Pharm Sci; 2010 May; 40(2):125-31. PubMed ID: 20307657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accelerator mass spectrometry analysis of background (14)C-concentrations in human blood: aiming at reference data for further microdosing studies.
    Minamimoto R; Hamabe Y; Miyaoka T; Hara T; Yoshida K; Oka T; Inoue T
    Ann Nucl Med; 2008 Dec; 22(10):883-9. PubMed ID: 19142707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
    Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positron emission tomography for use in microdosing studies.
    Wagner CC; Müller M; Lappin G; Langer O
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):104-10. PubMed ID: 18175273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines.
    Alavijeh MS; Palmer AM
    IDrugs; 2004 Aug; 7(8):755-63. PubMed ID: 15334309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolism and pharmacokinetics in children and the elderly.
    Pelkonen O
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):147-8. PubMed ID: 17428146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.